• Joana Enrera posted an update in the group Group logo of MT 30 - GH (Lec)MT 30 – GH (Lec) 1 week, 2 days ago

    Hello everyone! check out this article I found at Science Direct. The article “Arterial wall histology in chronic pulsatile-flow and continuous-flow device circulatory support” mentioned that end-stage heart failure can be treated using continuous-flow (CF) ventricular assist devices (VADs). However, the impact of long-term CF with no peripheral arterial wall movements on blood pressure regulation and end-organ arterial wall sclerosis is still unconfirmed, particularly in the case of long-term support.

    A ventricular assist device (VAD) is also known as a mechanical circulatory support device. It aids in the pumping of blood from your heart’s lower chambers (ventricles) to the rest of your body. So basically, while the patient waits for a heart transplant, it is recommended to undergo a surgery to implant a VAD to help the heart produce enough blood flow. Although a VAD can be implanted in either or both ventricles of the heart, the left ventricle is the most common location. It’s known as a left ventricular assist device when it’s implanted in the left ventricle (LVAD). Current LVADs maintain a continuous blood supply from your heart to your body. These LVADs are known as continuous flow devices. The article stated that they used the continuous-flow (CF) ventricular assist devices (VADs) to treat the end-stage heart failure and this is because this therapy showed significant result in offering survival, functional, and quality-of-life advantages. According to the histologic examinations in the article, there were no significant differences in artery wall features between Pulsatile-flow (PF) and CF devices. Therefore, long-term mechanical circulatory support with CF devices has little effect on the end-organ vasculature’s arterial wall characteristics.

    Link to the article:

you're currently offline

New Report